PURPOSE: Chronic Obstructive Pulmonary Disease (COPD) is a common disease worldwide. There are no reports about the prevalence of COPD in the United Arab Emirates (U.A.E.). We therefore conducted a study to determine the prevalence of COPD in U.A.E.
METHODS: This cross-sectional study is being conducted at the division of Respiratory medicine, Zayed Military Hospital, UAE. Individuals were randomly sampled using a sampling frame of individuals working for the military and their dependents (including parents). Inclusion criteria were (1) age ≥ 40 years and (2) ability to perform spirometry. Exclusion criteria were (1) subjects with mental alterations and (2) contraindication to Salbutamol. After written informed consent, all participants were being interviewed using a specially developed questionnaire followed by spirometery before and after 5 mg of nebulized Salbutamol using a spirometer standardized according to American Thoracic Society recommendations. Global Initiative for Chronic Obstructive Lung Disease (GOLD) definition i.e. FEV1 / FVC < 70% post bronchodilation was being used to diagnose COPD.
RESULTS: Out of a targeted 1000 subjects, 218 have been studied so far. Mean age of participants is 58.5 years.10 subjects met the COPD diagnosis criteria (4.6%). Mean FEV1 among the 10 was 1.99 Litre. Key Words: COPD prevalence. U.A.E. Abbreviations: FEV1 - forced expiratory volume in first second. FVC - forced vital capacity.
CONCLUSION: COPD prevalence in U.A.E. is comparable to other countries.
CLINICAL IMPLICATIONS: This study provides the first data on COPD prevalence in U.A.E. We included potentially new risk factors for COPD that were not previously studied. Examples: Shisha smoking and scent/bakhour inhalation which is unique to the arabic culture. We expect to have enough power to analyze their impact at the end of the study.
DISCLOSURE: Ashraf Alzaabi, Grant monies (from industry related sources) Boehringer Ingelheim has paid a total of 10,000 dollars to support the personnel doing the data entry, designing the database and the epidemiologist analysing the data. No money was paid to me.; No Product/Research Disclosure Information